Generate:Biomedicines Tech Stack
Generative biology platform advancing protein therapeutics through Phase 3 clinical programs
Generate:Biomedicines uses generative AI (PyTorch, JAX, TensorFlow) to design protein therapeutics, now in late-stage development with active Phase 3 respiratory trials and expanding quality/clinical infrastructure. The hiring mix—heavily weighted toward research and clinical leadership, with a dedicated CryoEM head and QMS focus—reflects a shift from model-building toward manufacturing scale and regulatory readiness. Pain points (inspection readiness, GCP compliance, cryo-EM bottlenecks) signal the company is navigating the transition from computational discovery into regulated drug development.
Tech Stack 20 technologies
What Generate:Biomedicines Is Building
◆Challenges
- Late-stage development
- Inspection readiness
- Global gcp compliance
- Managing external manufacturing relationships
- Scientific bottleneck in cryo-electron microscopy
- Building quality organization for growth
- Executing global clinical trials
- Reducing toil
- Reducing manual operations
- Global regulatory interactions
▲Active Projects
- Clinical trials
- Qms maintenance for clinical and pharmacovigilance
- Building and evaluating models that predict biophysical properties or drug-like properties
- Inspection readiness program
- Phase 3 asthma and copd studies
- Late-stage respiratory programs
- Modeling protein interactions using generative models
- Building generative models of protein sequence and structure
- Gcp & gpv quality strategy across clinical programs
- Vendor governance
Hiring Activity
Department
Seniority
Notable leadership hires: Director, GCP & GPV, CryoEM Head, Head of Quality, Clinical Development Lead, Therapeutic Applications Lead
